Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events
If you need an accessible version of this item, please submit a remediation request.
Date
2014-11
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Wiley Blackwell (John Wiley & Sons)
Abstract
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Sozio, M. S., & Chalasani, N. (2014). Activated Recombinant Factor VIIa should not be used in patients with refractory variceal bleeding – it is mostly ineffective, is expensive, and may rarely cause serious adverse events. Hepatology (Baltimore, Md.), 60(5), 1786–1788. http://doi.org/10.1002/hep.27363
ISSN
1527-3350
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Hepatology (Baltimore, Md.)
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Author's manuscript